- Home
- AQMS vs BOLT Comparison
AQMS vs BOLT Comparison
Compare AQMS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQMS | BOLT |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 10.5M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AQMS | BOLT |
|---|---|---|
| Price | $5.49 | $4.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 47.1K | 24.6K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,100,000.00 | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $600.00 | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.34 | $0.26 |
| 52 Week High | $39.37 | $7.35 |
Technical Indicators
Market Signals| Indicator | AQMS | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 71.73 | 49.75 |
| Support Level | $4.58 | $4.30 |
| Resistance Level | $8.37 | $5.22 |
| Average True Range (ATR) | 0.34 | 0.46 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 92.30 | 24.19 |
Price Performance
Historical ComparisonAbout AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.